Pharma Bavaria International GmbH

pharma-bavaria.com

Pharma Bavaria International is a global reach company that distributes and promotes high-quality pharmaceuticals with well-researched ingredients. In line with our vision - Access to Quality Healthcare - we offer a vast portfolio of prescription’s medicines that includes different therapeutic options for different pathologies, plus Pharma Bavaria International has LAB BOTANIC BAVARIA, an umbrella that covers OTCs and a range of herbal/supplement products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

TRIMAS CLOSES ON ACQUISITION OF OMEGA

TriMas | December 21, 2021

news image

TriMasannounced that it has closed the acquisition of Omega Plastics (“Omega”), a manufacturer of custom components and tooling for medical, as well as industrial applications, adding to TriMas’ Packaging group. Omega leverages its core injection molding capabilities, ISO Class 8 clean room and advanced in-house tool making capabilities, to provide its customers a faster product development cycle, from prototype development, testing and validation, to short...

Read More

PHARMA TECH

BEIGENE-NOVARTIS PD-1 DEAL; SINOVAC VACCINE; CELLTRION ANTIBODY COVID-19 DATA

Novartis | January 19, 2021

news image

Novartis plunked down up to $2.2 billion for BeiGene's China-approved PD-1 drug tislelizumab to complement its own checkpoint inhibitor. Hear what BeiGene CEO John Oyler has to say about tislelizumab's position in and outside China. Sinovac's COVID-19 vaccine reported confusing data from Brazil, raising doubt about its true efficacy. Celltron's anti-SARS-CoV-2 antibody improved patients' outcomes in a phase 2/3 trial. And more. Novartis paid $650 million upfron...

Read More

DECK 7 FRAMEWORK FOR DIGITAL™ REDEFINES ITS B2B MODEL FOR 2020 LEAD-GEN GOALS

DECK 7 | February 04, 2020

news image

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners...

Read More

ASTRAZENECA SPINOFF VIELA BIO SCORED ITS FIRST FDA NOD. CAN IT FACE DOWN HEAVYWEIGHT RIVALS?

Fiercepharma | June 16, 2020

news image

Two years after launching, AstraZeneca spinoff Viela Bio has its first FDA approval in Uplinza following Friday's nod to treat certain patients with neuromyelitis optica spectrum disorder. Analysts expect that the medicine, which won approval to treat patients who are anti-AQP4 antibody positive, can generate $586 million by 2026, according to Evaluate. But the competitive landscape could pose a challenge for the biotech's first launch. Doctors could prescribe Roche’s Rituxan or it...

Read More
news image

BUSINESS INSIGHTS

TRIMAS CLOSES ON ACQUISITION OF OMEGA

TriMas | December 21, 2021

TriMasannounced that it has closed the acquisition of Omega Plastics (“Omega”), a manufacturer of custom components and tooling for medical, as well as industrial applications, adding to TriMas’ Packaging group. Omega leverages its core injection molding capabilities, ISO Class 8 clean room and advanced in-house tool making capabilities, to provide its customers a faster product development cycle, from prototype development, testing and validation, to short...

Read More
news image

PHARMA TECH

BEIGENE-NOVARTIS PD-1 DEAL; SINOVAC VACCINE; CELLTRION ANTIBODY COVID-19 DATA

Novartis | January 19, 2021

Novartis plunked down up to $2.2 billion for BeiGene's China-approved PD-1 drug tislelizumab to complement its own checkpoint inhibitor. Hear what BeiGene CEO John Oyler has to say about tislelizumab's position in and outside China. Sinovac's COVID-19 vaccine reported confusing data from Brazil, raising doubt about its true efficacy. Celltron's anti-SARS-CoV-2 antibody improved patients' outcomes in a phase 2/3 trial. And more. Novartis paid $650 million upfron...

Read More
news image

DECK 7 FRAMEWORK FOR DIGITAL™ REDEFINES ITS B2B MODEL FOR 2020 LEAD-GEN GOALS

DECK 7 | February 04, 2020

DECK 7 Inc., a top lead generation company based in San Diego, California, has gone beyond its peers and competitors in their digital marketing efforts for 2020. An esteemed digital marketing and media company, known for executing campaign management and content services to its clients and partners worldwide, DECK 7 has built a comprehensive system to track buyers and influencers, build behavioral models, and putting all the vast intelligence it generates into the hands of its marketing partners...

Read More
news image

ASTRAZENECA SPINOFF VIELA BIO SCORED ITS FIRST FDA NOD. CAN IT FACE DOWN HEAVYWEIGHT RIVALS?

Fiercepharma | June 16, 2020

Two years after launching, AstraZeneca spinoff Viela Bio has its first FDA approval in Uplinza following Friday's nod to treat certain patients with neuromyelitis optica spectrum disorder. Analysts expect that the medicine, which won approval to treat patients who are anti-AQP4 antibody positive, can generate $586 million by 2026, according to Evaluate. But the competitive landscape could pose a challenge for the biotech's first launch. Doctors could prescribe Roche’s Rituxan or it...

Read More